Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Enfermedad de Alzheimer y Demencias

765 ARTÍCULOS , VIENDO DEL 706 AL 720

Clusterin is a Potential Therapeutic Target in Alzheimer's Disease

Palihati N, Tang Y, Yin Y, Yu D, Liu G, Quan Z, Ni J, Yan Y, Qing H.

Mol Neurobiol. 2024 Jul;61(7):3836-3850. doi: 10.1007/s12035-023-03801-1. Epub 2023 Nov 29.

Unraveling the role of miRNAs in the diagnosis, progression, and therapeutic intervention of Alzheimer's disease

Abdelmaksoud NM, Sallam AM, Abulsoud AI, El-Dakroury WA, Abdel Mageed SS, Al-Noshokaty TM, Elrebehy MA, Elshaer SS, Mahmoud NA, Fathi D, Rizk NI, Elballal MS, Mohammed OA, Abdel-Reheim MA, Zaki MB, Saber S, Doghish AS.

Pathol Res Pract. 2024 Jan;253:155007. doi: 10.1016/j.prp.2023.155007. Epub 2023 Dec 4.

Therapeutic implications of glycogen synthase kinase-3β in Alzheimer's disease: a novel therapeutic target

Mandlik DS, Mandlik SK, S A.

Int J Neurosci. 2024 Jun;134(6):603-619. doi: 10.1080/00207454.2022.2130297. Epub 2022 Oct 10.

Opportunities and challenges for the development of M(1) muscarinic receptor positive allosteric modulators in the treatment for neurocognitive deficits

Nguyen HTM, van der Westhuizen ET, Langmead CJ, Tobin AB, Sexton PM, Christopoulos A, Valant C.

Br J Pharmacol. 2024 Jul;181(14):2114-2142. doi: 10.1111/bph.15982. Epub 2022 Dec 4.

Interventions focusing on learning pre-transfer wheelchair manipulation in a patient with severe Alzheimer's disease: a case report

Nakagawa K, Kanai S, Kitakaze S, Okamura H.

Physiother Theory Pract. 2024 May;40(5):1091-1099. doi: 10.1080/09593985.2022.2149287. Epub 2022 Nov 21.

Study rationale and baseline data for pilot trial of dronabinol adjunctive treatment of agitation in Alzheimer's dementia (THC-AD)

Cohen LM, Ash E, Outen JD, Vandrey R, Amjad H, Agronin M, Burhanullah MH, Walsh P, Wilkins JM, Leoutsakos JM, Nowrangi MA, Harper D, Rosenberg PB, Forester BP.

Int Psychogeriatr. 2024 Dec;36(12):1245-1250. doi: 10.1017/S1041610221001150. Epub 2021 Oct 11.

Conquering Insulin Network Dysfunctions in Alzheimer's Disease: Where Are We Today?

de la Monte SM.

J Alzheimers Dis. 2024;101(s1):S317-S343. doi: 10.3233/JAD-240069.

Chiral nanomaterial-based approaches for diagnosis and treatment of protein-aggregated neurodiseases: current status and future opportunities

Pranav, Bajpai A, Dwivedi PK, Sivakumar S.

J Mater Chem B. 2024 Feb 21;12(8):1991-2005. doi: 10.1039/d3tb02381h.

Death-associated protein kinase 1 as a therapeutic target for Alzheimer's disease

Zhang T, Kim BM, Lee TH.

Transl Neurodegener. 2024 Jan 9;13(1):4. doi: 10.1186/s40035-023-00395-5.

Incretin Mimetics as Potential Disease Modifying Treatment for Alzheimer's Disease

Crook H, Edison P.

J Alzheimers Dis. 2024;101(s1):S357-S370. doi: 10.3233/JAD-240730.

Novel insights into the activating transcription factor 4 in Alzheimer's disease and associated aging-related diseases: Mechanisms and therapeutic implications

Zhang N, Nao J, Zhang S, Dong X.

Front Neuroendocrinol. 2024 Jul;74:101144. doi: 10.1016/j.yfrne.2024.101144. Epub 2024 May 24.

The multifaceted functions of β-arrestins and their therapeutic potential in neurodegenerative diseases

Kee TR, Khan SA, Neidhart MB, Masters BM, Zhao VK, Kim YK, McGill Percy KC, Woo JA.

Exp Mol Med. 2024 Feb;56(1):129-141. doi: 10.1038/s12276-023-01144-4. Epub 2024 Jan 11.

The Use of Neurotrophic Factors as a Promising Strategy for the Treatment of Neurodegenerative Diseases (Review)

Fursa GA, Andretsova SS, Shishkina VS, Voronova AD, Karsuntseva EK, Chadin AV, Reshetov IV, Stepanova OV, Chekhonin VP.

Bull Exp Biol Med. 2024 Aug;177(4):517-527. doi: 10.1007/s10517-024-06218-5. Epub 2024 Sep 12.

Natural Compounds as Inhibitors of Aβ Peptide and Tau Aggregation

Monteiro KLC, de Aquino TM, da Silva-Júnior EF.

CNS Neurol Disord Drug Targets. 2024;23(10):1234-1250. doi: 10.2174/0118715273273539231114095300.

Designing and Formulation of Nanocarriers for "Alzheimer's and Parkinson's" Early Detection and Therapy

Abujamai J, Satar R, Ansari SA.

CNS Neurol Disord Drug Targets. 2024;23(10):1251-1262. doi: 10.2174/0118715273297024240201055550.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias